Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844997 | 1.00 | TYMS (0.45) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL887563 | 0.94 | TYMS (0.44) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL19500417 | 0.92 | TYMS (0.44) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL14286636 | 0.88 | TYMS (0.48) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL5064823 | 0.88 | TYMS (0.48) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL8159110 | 0.88 | TYMS (0.46) | TYMSTK1TYMP | |
| SCHEMBL8166332 | 0.86 | TYMS (0.47) | TYMSTK1TYMP | |
| SCHEMBL4814982 | 0.84 | TYMS (0.44) | TYMSTYMP | |
| SCHEMBL3088129 | 0.83 | CYP1A2 (0.60) | TYMSCYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL28636366 | 0.83 | TYMS (0.30) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353872-A1 | Ligand-Modified Oligonucleotides | NOVO NORDISK A/S (DK) | 2025-11-20 | — | — | US | disclosed |
| EP-3865576-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3569711-B1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS INC (US) | 2021-02-03 | — | — | EP | disclosed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-3569711-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3234132-B1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
| EP-3234132-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100401-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | TYMS 85/4885CYP1A2 4778/4885CYP3A4 4836/4885 |
| US-20250353872-A1 | Ligand-Modified Oligonucleotides | NCL, ADAR, NSUN3 | TYMS 49/4885CYP1A2 4834/4885CYP3A4 4848/4885 |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | ADAR, NCL, SSU72 | TYMS 85/4885CYP1A2 4778/4885CYP3A4 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.